Latest Celldex Therapeutics Stories

2008-11-12 12:00:31

Celldex Therapeutics, an integrated biopharmaceutical company, has signed an exclusive patent and know-how license agreement with the University of Southampton, UK, to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers. In preclinical models, antibodies to CD27 have been shown to mediate anti-tumor effects alone, and may be particularly effective in combination with other immunotherapies. Financial terms of the transaction were not...

2008-11-04 03:00:05

Celldex Therapeutics, an integrated biopharmaceutical company, has announced initial results from multi-center Phase I clinical trials of its cancer vaccine candidate, CDX-1307, combined with GM-CSF. These data provide the basis for the ongoing assessment of CDX-1307 combined with more potent adjuvants with data expected in the first half of 2009. The Phase I studies are open-label, dose-escalating clinical trials in patients with incurable breast, bladder, pancreatic, or colorectal cancer,...

2008-10-03 09:00:38

Celldex Therapeutics, an integrated biopharmaceutical company, has received a milestone payment of $10 million from an affiliate of Paul Capital Healthcare. The payment was triggered by the market launch of Rotarix in the US. Rotarix is marketed worldwide by GlaxoSmithKline. John Leone, a partner at Paul Capital Healthcare, said: "In purchasing a portion of Celldex's Rotarix royalty stream, Paul Capital Healthcare has helped Celldex to monetize a previously under-appreciated asset. The...

Word of the Day
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'karpos', fruit.